An interventional study of Radical Prostatectomy and Precision Prostatectomy in Prostatectomy, sponsored by Henry Ford Health System. Recruiting at 1 site in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Henry Ford Health System · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.
Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 632nd largest by planned enrollment of the 3,024 interventional ones that give a count, is one of 176 that started in 2026, is one of 764 with no phase, reaches primary completion later than 555 of the 968 other live ones, and was the 3,431st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–80 · Men only
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 50–75 · Men only · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,597 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 899 · Phase 2 1,384 · Phase 3 321 · Phase 4 50
First in 1988; this study’s year is marked. 176 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 48 across the 3,024 interventional studies, 158 across the 478 observational. Of the 2,360 that completed or were terminated, 997 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
922 of 3,597 have an industry lead sponsor. The 10 most frequent:
Henry Ford Health System is the lead sponsor of 304 studies on the registry; 51 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 26 (70%) have results posted.
Henry Ford Health System has 7 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
334 of the studies in Prostatic Neoplasms with a site in United States that are under way reach primary completion within a year, 24 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06970847Phase 3Clarity Pharmaceuticals Ltd64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | 2026-12-31 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT07427043Phase 3Brigham and Women's HospitalRobotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) | 2026-12-31 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
Add all 334 to your calendar (.ics) → With an account.
Among the 3,597 studies in Prostatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile dysfunction (50-70%) and urinary incontinence (5-20%). To address these issues, precision prostatectomy (PP) has emerged as a novel surgical approach that preserves functional structures while removing >90% of prostate tissue.
PP is thought to provide superior functional outcomes with acceptable oncological control by preserving the capsule, seminal vesicle (SV), and the surrounding neuronal nitric oxide synthase (nNOS) producing nerves on the side opposite to the dominant nodule while maximizing prostatic tissue removal. Early reports of PP demonstrate promising functional outcomes, with 90% of patients retaining sexual potency (Sexual Health Inventory for Men [SHIM] score ≥17) and 100% achieving continence (0-1 pads/day) by 12 months postoperatively. Importantly, PP only requires a different surgical technique, no more equipment, time, or labor is required. This means that there is no additional charge to patients, and it is covered the same by health insurance.
While there are early results suggesting the superiority of PP, no randomized trials have yet to be performed. This study has two main aims: to demonstrate superiority of PP in terms of functional recovery while also establishing non-inferiority in oncologic outcomes compared to RP. This dual objective reflects the potential of PP to improve quality of life without compromising cancer control.
Eligible patients will be randomized to either RP, which is the current standard of care, or PP using random blocked randomization using the Zelen design.
The outcomes of interest will be measured at 12 months post-surgery. Functional outcomes will be measured using SHIM scores at 12 months and the number of pads used per day. Meanwhile, oncological outcomes will be measured by whether patients have received secondary prostate cancer treatment at 12 months post-surgery. These items are collected as part of standard of care of all patients 12 months after prostatectomy. RP and PP patients' sexual function recovery (SHIM ≥17 vs SHIM \< 17), as well as the proportion reaching continence (≤1 pad per day, > 1 pad per day) will be compared.
RP has been shown to be effective in terms of oncological outcomes, though it has also been shown to be related to incontinence and erectile dysfunction. Early results have suggested that PP is superior in terms of functional outcomes while being as good as RP in terms of oncological outcomes, though no randomized trials have been conducted. This trial will address this literature gap and could lead to patients receiving care that is as effective ontologically and superior in terms of functional recovery as the current standard of care. This could lead to improved quality of life for patients after surgery. Considering that prostate cancer is the most common non-cutaneous carcinoma among men in the United States, this has the potential to help thousands of men per year by improving their quality of life without sacrificing oncological outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Androgen deprivation therapy within 6 months.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm is the control arm and consists of the current standard of care. Patients in this arm receive a radical prostatectomy.
Procedure: Radical Prostatectomy
This arm is the treatment arm and consists of patients who receive a Precision Prostatectomy.
Procedure: Precision Prostatectomy
In radical prostatectomies, the entire prostate as well as much of the surrounding tissue is removed.
Also known as: Prostatectomy
The surgical approach is very similar to a radical prostatectomy. The difference is that in precision prostatectomy, some of the prostate, including the nerves which might be integral to continence and erectile function are protected and not removed, unlike with traditional radical prostatectomies.
Sexual Health
Patients' sexual health and function is measured by the Sexual Health Inventory for Men (SHIM). A SHIM score \> 16 is considered sexually healthy.
Time frame: Before surgery, 3 months post-surgery, 12 months post-surgery
Social Continence
Continence is determined by the number of pads used per day by patients. Social continence is defined as \< 2 pads per day.
Time frame: 12 months post-surgery.
Oncological outcomes
The number of patients who undergo secondary treatment.
Time frame: 12-months post-surgery
Plan to share: No — At this time we do not plan on making a deidentified dataset and PHI cannot be shared per institutional policies. We will consider sharing deidentified data upon request.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 23 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.